Efficacy and Tolerability of Erenumab for Prevention of Episodic Migraine in India - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35936611/
1 Department of Neurology, Govind Ballabh Pant Hospital, New Delhi, India. 2 Department of Neurology, Yashoda Hospital, Hyderabad, Telangana, India. 3 Department of Neurology, Calcutta Medical Research Centre, Kolkata, West...
Conclusion: Both doses of erenumab showed numerical improvement for efficacy endpoints and were well-tolerated in the Indian population. No new safety signals were reported.
Circadian Pain Patterns in Human Pain Conditions - A Systematic Review - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35869813/
doi: 10.1111/papr.13149. Online ahead of print. 1 Department of Anesthesiology, Advocate Illinois Masonic Medical Center, Chicago, IL, USA. 2 Department of Anesthesiology, University of Illinois, Chicago, IL, USA. 3 Department...
Conclusion: The results of this review suggest that an understanding of diurnal variation may help improve therapeutic strategies in pain management, for instance through analgesic titration.
-
Huma Sheikh, CEO, NY Neurology Medicine, PC4yrThis is present in many headache syndromes.
CGRP-Targeted Therapy for Episodic and Chronic Cluster Headache - Current Pain and Headache Reports
Source : https://link.springer.com/article/10.1007/s11916-022-01070-6
Purpose of Review Chronic cluster headache (CH) substantially affects patients' quality of life, and treatment remains challenging. The current article reviewed controlled studies for new treatment options targeting calcitonin gene-related...
Summary: There are no randomized controlled trials for CGRP-targeted therapies that showed efficacy for chronic CH prevention. The different responses to galcanezumab between episodic and chronic CH may be due to the study design, i.e., the allowance of concomitant preventive therapies in the chronic CH study but not in the episodic CH study....
-
Huma Sheikh, CEO, NY Neurology Medicine, PC4yrNeed more and more to allow insurance coverage.
Long-term reductions in disease impact in patients with chronic migraine following preventive treatment with eptinezumab - BMC Neurology
Source : https://bmcneurol.biomedcentral.com/articles/10.1186/s12883-022-02774-3
Background Eptinezumab is an anti-calcitonin gene-related peptide humanized monoclonal antibody approved for the preventive treatment of migraine in adults. The PREVAIL study demonstrated a favorable safety profile with sustained reductions...
Conclusions: Long-term treatment with eptinezumab in patients with CM suggested sustained reductions in MIDAS-quantified disability, consistent with the sustained reductions in headache frequency and pain severity.
-
Huma Sheikh, CEO, NY Neurology Medicine, PC4yrHappy to see real life follow up studies.
Migraine among Saudi Arabians | IJGM
Mammalian mitochondrion is found to own a specific deoxyribonucleic acid (DNA) in its matrix. Mitochondrion DNA (mtDNA) is responsible for the transcription of essential proteins for the mitochondrial function. As...
Conclusion: This is the first study to demonstrate the association of mtDNA variations with migraine in the Saudi population. The current findings will help to highlight the significance of mtDNA mutations to migraine pathophysiology and will serve as a reference data for larger national and international studies.
-
Huma Sheikh, CEO, NY Neurology Medicine, PC4yrVery interesting!